Data Breach Alert: Social media users highlighted a recent disclosure by Novo Nordisk regarding a breach involving clinical trials patient data. Observers noted the potential regulatory and reputational implications for the pharmaceutical giant amid heightened scrutiny of data security in healthcare. Discussions emphasized the need for robust incident response protocols across the sector.
Production Capacity Focus: Market participants on social media examined ongoing challenges with scaling manufacturing for key GLP-1 therapies like Wegovy. Analysts pointed to substantial investments in new facilities and partnerships as efforts to address supply constraints. Sentiment reflected caution around short-term volatility tied to demand-supply imbalances.
Valuation Debate: Traders debated the stock's premium valuation metrics, including forward price-to-cash-flow ratios around 28 times. Some expressed views that growth prospects support current levels, while others flagged risks from increasing competition. Overall, conversations conveyed a mixed outlook on future performance.
Note: This discussion summary was generated from an AI condensation of post data.
Novo Nordisk Revenue
Novo Nordisk had revenues of $15B in Q1 2026.
You can track NVO financials on Quiver Quantitative's NVO stock page.
You can access data on NVO stock through the Quiver Quantitative API.
Novo Nordisk Hedge Fund Activity
We have seen 571 institutional investors add shares of Novo Nordisk stock to their portfolio, and 901 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DODGE & COX added 19,333,750 shares (+inf%) to their portfolio in Q1 2026, for an estimated $693,211,606
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 9,884,077 shares (+808.8%) to their portfolio in Q1 2026, for an estimated $354,393,580
- FMR LLC removed 8,664,705 shares (-86.5%) from their portfolio in Q1 2026, for an estimated $310,672,997
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 7,827,491 shares (+inf%) to their portfolio in Q1 2026, for an estimated $280,654,689
- TWO SIGMA INVESTMENTS, LP added 5,943,310 shares (+1731.8%) to their portfolio in Q1 2026, for an estimated $213,097,380
- GOLDMAN SACHS GROUP INC removed 5,865,741 shares (-53.4%) from their portfolio in Q1 2026, for an estimated $210,316,143
- BOSTON PARTNERS removed 5,231,804 shares (-97.3%) from their portfolio in Q1 2026, for an estimated $187,586,332
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Novo Nordisk Price Targets
Multiple analysts have issued price targets for $NVO recently. We have seen 2 analysts offer price targets for $NVO in the last 6 months, with a median target of $57.25.
Here are some recent targets:
- James Quigley from Goldman Sachs set a target price of $41.0 on 03/02/2026
- An analyst from CICC set a target price of $73.5 on 01/09/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
